Unknown

Dataset Information

0

A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.


ABSTRACT: Biomarkers for patient selection are essential for the successful and rapid development of emerging targeted anti-cancer therapeutics. In this study, we report the discovery of a novel patient selection strategy for the p53-HDM2 inhibitor NVP-CGM097, currently under evaluation in clinical trials. By intersecting high-throughput cell line sensitivity data with genomic data, we have identified a gene expression signature consisting of 13 up-regulated genes that predicts for sensitivity to NVP-CGM097 in both cell lines and in patient-derived tumor xenograft models. Interestingly, these 13 genes are known p53 downstream target genes, suggesting that the identified gene signature reflects the presence of at least a partially activated p53 pathway in NVP-CGM097-sensitive tumors. Together, our findings provide evidence for the use of this newly identified predictive gene signature to refine the selection of patients with wild-type p53 tumors and increase the likelihood of response to treatment with p53-HDM2 inhibitors, such as NVP-CGM097.

SUBMITTER: Jeay S 

PROVIDER: S-EPMC4468608 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4596780 | biostudies-literature
| S-EPMC8405607 | biostudies-literature
| S-EPMC1765448 | biostudies-literature
| S-EPMC3262062 | biostudies-literature
| S-EPMC2740553 | biostudies-literature
| S-EPMC3785365 | biostudies-literature
| S-EPMC218704 | biostudies-literature
| S-EPMC2995991 | biostudies-literature
| S-EPMC4576826 | biostudies-literature